- CMTA Announces New Center of Excellence in KentuckyThe Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce it has awarded ...Read more ...
- CMTA-STAR Collaboration Celebrates a Decade of CMT Genetic Discovery Through the GENESIS DatabaseExciting progress from CMTA’s Strategy To Accelerate Research (STAR) program is once again highlighted with a recent publication celebrating a decade of CMT genomics discovery made possible by the GENESIS platform. This critically important CMTA-funded ...Read more ...
- Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of ExcellenceThe Charcot-Marie-Tooth Association (CMTA) congratulates CMTA-STAR Alliance Partner NMD Pharma A/S (NMD Pharma) on initiating its Phase II SYNAPSE-CMT trial. This significant milestone reflects a shared commitment to advancing therapeutic options for individuals living with ...Read more ...
- CMTA-INC Strategic Alliance Announces the 2025 Inherited Neuropathy FellowshipThe Charcot-Marie-Tooth Association (CMTA), through its strategic alliance with the Inherited Neuropathy Consortium (INC), is proud to announce the 2025 Inherited Neuropathy Fellowship. This one-year fellowship highlights how the CMTA-INC alliance drives progress by equipping ...Read more ...
- CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease TypesCMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic alliance with the Inherited Neuropathy Consortium The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at ...Read more ...